Stocks and Investing
Stocks and Investing
Thu, April 30, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Berens Maintained (BPMC) at Buy with Decreased Target to $88 on, Apr 30th, 2020
Andrew Berens of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Decreased Target from $103 to $88 on, Apr 30th, 2020.
Andrew has made no other calls on BPMC in the last 4 months.
There are 3 other peers that have a rating on BPMC. Out of the 3 peers that are also analyzing BPMC, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Andrew
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy with Decreased Target to $66 on, Wednesday, April 29th, 2020
- George Farmer of "BMO Capital" Maintained at Buy with Decreased Target to $75 on, Wednesday, April 29th, 2020
- Konstantinos Aprilakis of "JMP Securities" Maintained at Buy with Decreased Target to $103 on, Wednesday, April 29th, 2020